1. Introduction {#sec1}
===============

The presence of metabolic disorders such as glucose intolerance and dyslipidemia is associated with the incidence of cardiovascular disease (CVD) and is a cause of mortality \[[@B1], [@B2]\]. It has been reported that the components of metabolic syndrome (Mets), which include abdominal obesity, hypertension, impaired insulin tolerance with high fasting glucose levels, and elevated levels of triglycerides \[[@B3]--[@B5]\], are risk factors for CVD \[[@B6], [@B7]\]. Epidemiological and experimental studies have provided evidence of the relationship between cardiac dysfunction and diabetes mellitus (DM) \[[@B8]--[@B11]\]. Furthermore, hyperglycemia, hypertension, and dyslipidemia are associated with ongoing myocardial damage. These findings imply that there is a significant association between the severity of Mets and organ damage \[[@B12], [@B13]\]. However, a correlation between insulin resistance (IR) and cardiac dysfunction in the general population has not been established to date.

Clinical studies have shown that heart-type fatty acid-binding protein (H-FABP), which is rapidly released into the circulation from the damaged myocardium, may be a marker for myocardial damage not only in patients with ischemic heart disease but also in those with chronic heart failure \[[@B14]--[@B17]\]. Because the levels of H-FABP are correlated with the incidence of cardiac events in heart failure patients, the assessment of H-FABP levels may be of value to estimate the potential existence of cardiac damage in the general population \[[@B18], [@B19]\]. The effect of IR on myocardial damage in normal subjects, however, remains to be clarified. The purpose of this study was to investigate the association between IR and myocardial damage in healthy subjects.

2. Methods {#sec2}
==========

2.1. Study Design {#sec2.1}
-----------------

This study was part of the Molecular Epidemiological Study utilizing the Regional Characteristics of 21st Century Centers of Excellence (COE) Program and Global COE Program in Japan, as described in detail previously \[[@B20]\]. The study was approved by the institutional ethics committee and all participants provided written informed consent. The subjects included in the study were members of the general population with an age of 40 years and older from the town of Takahata in northern Japan. From June 2004 to November 2005, 1,380 men and 1,735 women were enrolled in the study. A total of 915 patients with incomplete data were excluded, and 2200 patients participated in the final study.

2.2. Clinical Assessments {#sec2.2}
-------------------------

The Takahata town study was based on a survey consisting of a self-administered questionnaire about lifestyle, blood pressure measurements, anthropometric measurements, and the collection of blood and urine specimens from the participants at annual health exams. Information concerning medical history, current medications, smoking habits, and alcohol intake was obtained from the self-reported questionnaire. Blood pressure was measured using a mercury manometer, with subjects resting in a seated position for at least 5 minutes before measurement.

2.3. Definition of Mets and IR {#sec2.3}
------------------------------

Mets was evaluated using the National Cholesterol Education program Adult Treatment Panel III (NCEP-ATP III) criteria \[[@B3]\]. The NCEP-ATP III criteria for abdominal obesity were modified by using body mass index (BMI) ≥ 25 kg/m^2^ instead of the waist circumference because obesity is defined as BMI ≥ 25 kg/m^2^ in Japan \[[@B21], [@B22]\]. Mets was defined on the basis of meeting at least 3 of the following 5 NCEP-ATP III criteria: BMI ≥ 25 kg/m^2^, elevated triglyceride (TG) ≥ 150 mg/dL, reduced high-density lipoprotein cholesterol (HDLc) \< 40 mg/dL in men and \< 50 mg/dL in women, elevated fasting blood sugar (FBS) ≥ 110 mg/dL or previously diagnosed diabetes mellitus, elevated blood pressure \[systolic blood pressure (sBP) ≥ 130 mmHg, and/or diastolic blood pressure (dBP) ≥ 85 mmHg\] or use of antihypertensive medication. Insulin tolerance was evaluated with the homeostasis model assessment ratio \[HOMA-R, HOMA-R = fasting insulin levels (IRI) × FBS × 1/405\], and IR was defined as HOMA-R \> 2.5 \[[@B23]\].

2.4. Definition of Latent and Ongoing Myocardial Damage {#sec2.4}
-------------------------------------------------------

The presence of latent and ongoing myocardial damage was defined as serum levels of heart type fatty acid binding protein (H-FABP) above 4.3 ng/mL as reported previously \[[@B16], [@B18]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

Data are presented as mean ± standard deviation (SD). Data that were not distributed normally were presented as medians and interquartile intervals. The unpaired Student\'s *t*-test and the chi-square test were used for comparisons between 2 groups of continuous and categorical variables, respectively. The Mann-Whitney *U*-test was used when data were not distributed normally. Comparisons of data among 3 groups categorized based on the presence of IR and Mets were performed by the Kruskal-Wallis test. Univariate and multivariate logistic analyses were performed to evaluate the association between IR and ongoing myocardial damage.

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

[Table 1](#tab1){ref-type="table"} lists the characteristics of the 2200 subjects. The proportion of men was 44.2%, and the mean age of the study subjects was 63 ± 10 years. Mean serum levels of brain natriuretic peptide (BNP) and H-FABP were 20.0 ng/L (interquartile range: 10.9--35.8) and 3.5 ng/mL (interquartile range: 2.6--4.7), respectively. Mean BMI was 23.0 ± 3.3 kg/m^2^; sBP and dBP were 134 ± 16 mmHg and 79 ± 10 mmHg, respectively. Serum FBS levels were 93 ± 12 mg/dL. Serum levels of total cholesterol (TC), TG, HDLc, and low-density lipoprotein cholesterol (LDLc) were 200 mg/dL (interquartile range: 179--221), 91 mg/dL (interquartile range: 68--125), 59 ± 15 mg/dL, and 124 ± 29 mg/dL, respectively. Estimated glomerular filtration rate was 96.0 mL/min/1.73 m^2^ (interquartile range: 82--110).

3.2. Classification of Subjects by the Presence of IR {#sec3.2}
-----------------------------------------------------

Subjects were divided into 3 groups according to the presence of IR and Mets, as shown in [Table 2](#tab2){ref-type="table"}. IR was associated with female gender; high BMI; high sBP and dBP; high LDLc, TG, and TC levels; and low BNP and HDLc levels compared to subjects without IR. Mets was associated with male gender; high BMI; high sBP and dBP; high LDLc, TG, and TC levels; and low BNP and HDLc levels compared to subjects without Mets. Serum H-FABP levels were significantly higher in subjects with IR and Mets than in those without IR. However, there was no significant difference between subjects with IR and those with Mets, as shown in [Figure 1](#fig1){ref-type="fig"}.

3.3. Classification by Gender {#sec3.3}
-----------------------------

It is well known that serum H-FABP level and other blood parameters differ according to gender \[[@B18]\]. We therefore divided subjects into 2 groups according to gender, as shown in [Table 3](#tab3){ref-type="table"}. Clinical characteristics were different between the 2 groups. However, serum H-FABP levels were significantly higher in subjects with IR and Mets than in those without IR in both groups regardless of gender, as shown in Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}.

3.4. Association between IR and Ongoing Myocardial Damage {#sec3.4}
---------------------------------------------------------

To investigate the contribution of IR to the increase of H-FABP levels in the asymptomatic general population, 1936 subjects without Mets were examined by univariate and multivariate logistic analyses. In the univariate logistic analysis, the presence of IR, age, gender, sBP, and serum levels of BNP and LDLc were associated with latent and ongoing myocardial damage, as shown in [Table 6](#tab6){ref-type="table"}. In the multivariate logistic analysis, the presence of IR was independently associated with the increase of H-FABP levels (OR: 1.6, 95% confidence interval 1.1--2.3) after adjusting for age, gender, serum BNP level, sBP, and serum LDLc level, as shown in [Table 3](#tab3){ref-type="table"}. Furthermore, the percentage of subjects with latent and ongoing myocardial damage was significantly higher in those with IR than in those without IR (8.27% versus 11.20%, *P* = 0.0478), as shown in [Figure 2](#fig2){ref-type="fig"}.

4. Discussion {#sec4}
=============

The findings of the present study are as follows: (1) H-FABP levels increased in association with IR and Mets in normal subjects; (2) multivariate logistic analysis revealed that the presence of IR was an independent risk factor for myocardial injury in the general population; (3) the prevalence of high H-FABP was more prevalent in subjects with IR than in those without IR.

Although patients with IR are often asymptomatic, this condition can lead to a multitude of diseases \[[@B24]\]. The early detection of metabolic disorder is important for the prevention of new-onset CVD. Physicians can only treat patients in the symptomatic state because asymptomatic subjects, such as those with IR, do not generally present to clinics or hospitals. Our study showed that latent and ongoing myocardial damage may occur in the early stages of metabolic disease, such as those characterized by the presence of IR. This suggests that early detection of latent and ongoing myocardial damage through population screening is essential to prevent future cardiovascular disorders.

Serum BNP is an established and commonly used marker for the detection of myocardial damage during screening evaluations \[[@B25]\]. However, in the present study, we measured serum H-FABP to detect latent and ongoing myocardial damage for the following reasons. First, several cohort studies have shown that high BMI is inversely correlated to serum BNP level \[[@B26]--[@B28]\]. The hypothesized mechanism underlying this inverse relationship has been described previously. Increased expression of natriuretic peptide clearance receptor by adipose tissue, which is shown in obese subjects, results in increased clearance of serum BNP \[[@B29]\]. Similarly, we also observed an inverse relationship between serum BNP level and IR in the present study. Thus, serum BNP appears to be inadequate to detect latent and ongoing myocardial damage in the early stages of metabolic disorder. Second, previous reports showed that serum H-FABP is a useful and sensitive marker for screening patients with latent and ongoing myocardial damage \[[@B14], [@B17], [@B19]\]. It is well known that serum H-FABP is rapidly released into the circulation from damaged myocardium; hence, it is used as a marker of acute coronary syndrome. On the other hand, there is evidence that disturbances in cardiac microvascular circulation caused by metabolic disorders and left ventricular hypertrophy induce myocardial hypoxia and cardiomyocyte injury and impair cardiac function \[[@B30]--[@B32]\]. Moreover, not only hypoxia, but also mechanical stretch, oxidative stress, inflammation, and apoptosis increase cardiomyocyte permeability, resulting in elevated levels of myocardial cytosolic markers in patients with heart failure \[[@B33]--[@B36]\]. Previously, we demonstrated that increased serum H-FABP level is associated with the exacerbation of chronic heart failure and thus provides prognostic information \[[@B15], [@B16]\]. These studies showed that patients with high serum levels of H-FABP had a significantly higher rate of cardiac events than those with normal H-FABP levels (34% versus 4%, *P* \< 0.001). Furthermore, these studies suggested that serum H-FABP level was an independent predictor of future cardiac events (*χ* ^2^ = 7.397, *P* \< 0.01). Similarly, minimally increased levels of troponin T are associated with mortality and morbidity in patients with chronic heart failure \[[@B37], [@B38]\].

In this study, we demonstrated that H-FABP but not BNP was higher in subjects with IR and Mets than in those without these conditions, suggesting that measurement of H-FABP might be suitable to predict the occurrence of myocardial damage in subjects with metabolic disorder.

There were several limitations associated with our study. First, we modified the NCEP-ATP III criteria for abdominal obesity by using body mass index (BMI) ≥ 25 kg/m^2^ instead of the waist circumference to evaluate metabolic syndrome. We used BMI instead of the waist circumference because the definition of waist circumference is unclear in Japan, especially in women \[[@B39]\]. On the other hand, BMI as a criterion for obesity has been clearly defined as BMI ≥ 25 kg/m^2^ in the Japanese general population \[[@B21]\]. Second, we did not detect latent and ongoing myocardial damage by visual methods such as echocardiography or myocardial scintigraphy. The association between alterations in diastolic function and metabolic disorder has been reported \[[@B40]\], and the correlation between the results of myocardial scintigraphy and myocardial damage in subjects with diastolic dysfunction was also been shown \[[@B41]\]. In addition, prior reports have shown that H-FABP levels are correlated with the severity of myocardial injury evaluated by myocardial scintigraphy \[[@B42]\]. Taken together, these findings suggest that the measurement of serum levels of H-FABP might be appropriate for a population-based study. Third, our data are cross-sectional and cannot demonstrate longitudinal progression of cardiovascular disorder and cannot establish causal relationship between IR and obvious heart disease. Future studies should be focused on assessing longitudinal progression.

5. Conclusion {#sec5}
=============

The presence of IR is related to latent and ongoing myocardial damage in normal subjects, which suggests that myocardial damage occurs in the early state of metabolic disorder. Future studies should be aimed at developing effective strategies for the treatment of IR to prevent myocardial damage and improve clinical outcomes.
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![Serum levels of H-FABP in the study population. Subjects with and without insulin resistance (IR) and metabolic syndrome (Mets) were included. In comparison to IR (−) subjects, subjects with IR and Mets showed an increase in H-FABP levels. Data are expressed as mean ± SD. \**P* \< 0.05 versus subjects without IR.](EDR2012-815098.001){#fig1}

![Comparison of latent and ongoing myocardial damage between subjects with and without IR. Latent and ongoing myocardial damage was defined as serum levels of heart type fatty acid binding protein (H-FABP) above 4.3 ng/mL. In comparison to IR (−) subjects, those with IR showed a higher incidence of myocardial damage.](EDR2012-815098.002){#fig2}

###### 

Comparisons of clinical characteristics of 2200 subjects.

  ----------------------------- -------------------
  Age (years)\*                 69.1 ± 12.6
  Gender (male/female)          973/1227
  BMI (kg/m^2^)\*               23.0 ± 3.3
  sBP (mm Hg)\*                 134 ± 16
  dBP (mm Hg)\*                 79 ± 10
  BNP (pg/mL)\*\*               20.0 (10.9--35.8)
  TC (mg/dL)\*\*                200 (179--221)
  TG (mg/dL)\*\*                91 (68--125)
  HDLc (mg/dL)\*                59 ± 15
  LDLc (mg/dL)\*                124 ± 29
  eGFR (mL/min/1.73 m^2^)\*\*   96 (82--110)
  H-FABP (ng/mL)\*\*            3.5 (2.6--4.7)
  ----------------------------- -------------------

BMI: body mass index; BNP: brain natriuretic peptide; TC: total cholesterol; TG: triglyceride; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; H-FABP: heart type fatty acid binding protein; sBP: systolic blood pressure; dBP: diastolic blood pressure; Data are presented as \*mean ± S.D; \*\*median (interquartile range).

###### 

Comparisons of clinical characteristics of patients with and without IR.

                            IR (−)              IR (+)               Mets
  ------------------------- ------------------- -------------------- ---------------------
  Age                       63 ± 10             63 ± 10              63 ± 10
  Male                      659 (46.2%)         169 (33.2%)\*        145 (54.9%)^∗\#^
  BMI                       21.9 ± 2.8          24.4 ± 3.2\*         26.1 ± 2.5^∗\#^
  sBP                       132 ± 16            136 ± 15\*           134 ± 14\*
  dBP                       78 ± 10             80 ± 10\*            84 ± 8^∗\#^
  BNP (pg/mL)               21.5 (12.1--37.4)   17.1 (9.5--30.5)\*   17.5 (9.4--33.6)\*
  TC (g/dL)                 197 (177--217)      204 (187--226)\*     205 (182--229)\*
  TG (g/dL)                 81 (63--106)        101 (77--128)\*      171 (150--224)^∗\#^
  HDL (g/dL)                61 ± 14             58 ± 13\*            46 ± 12^∗\#^
  LDL (g/dL)                122 ± 29            131 ± 28\*           124 ± 30^∗\#^
  eGFR (mL/min/1.73 m^2^)   97 (82--112)        98 (83--111)         86 (74--102)^∗\#^
  H-FABP (ng/mL)            3.5 (2.6--4.6)      3.6 (2.6--4.7)\*     3.7 (2.8--5.1)\*

BMI: body mass index; BNP: brain natriuretic peptide; TC: total cholesterol; TG: triglyceride; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; H-FABP: heart type fatty acid binding protein; sBP: systolic blood pressure; dBP: diastolic blood pressure; Data are presented as mean ± S.D or median (interquartile range). \**P* \< 0.05 versus IR (−); ^\#^ *P* \< 0.05 versus IR (+).

###### 

Comparisons of clinical characteristics in male and female subjects.

                                Male               Female
  ----------------------------- ------------------ -------------------
  Age (years)\*                 64.0 ± 10.2        62.7 ± 10.0^†^
  BMI (kg/m^2^)\*               22.9 ± 3.0         23.1 ± 3.5
  sBP (mm Hg)\*                 136 ± 16           133 ± 16^†^
  dBP (mm Hg)\*                 82 ± 10            77 ± 9^†^
  BNP (pg/mL)\*\*               17.6 (9.3--36.1)   21.4 (12.4--35.3)
  TC (mg/dL)\*\*                191 (173--211)     206 (187--226)^†^
  TG (mg/dL)\*\*                95 (70--135)       89 (66--117)^†^
  HDLc (mg/dL)\*                56 ± 14            61 ± 14^†^
  LDLc (mg/dL)\*                119 ± 28           129 ± 28^†^
  eGFR (mL/min/1.73 m^2^)\*\*   82 (72--90)        106 (97--124)^†^
  H-FABP (ng/mL)\*\*            3.7 (2.8--4.8)     3.4 (2.6--4.6)^†^

BMI: body mass index; BNP: brain natriuretic peptide; TC: total cholesterol; TG: triglyceride; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; H-FABP: heart type fatty acid binding protein; sBP: systolic blood pressure; dBP: diastolic blood pressure; Data are presented as \*mean ± S.D; \*\*median (interquartile range); ^†^ *P* \< 0.05 versus male.

###### 

Comparisons of clinical characteristics of patients with and without IR and Mets in male.

                            IR (−)              IR (+)               Mets (+)
  ------------------------- ------------------- -------------------- ---------------------
  Age (years)               64 ± 10             64 ± 10              63 ± 8
  BMI (kg/m^2^)             22.0 ± 3.0          24.2 ± 2.8\*         25.9 ± 2.3^∗\#^
  sBP (mm Hg)               135 ± 16            138 ± 16\*           142 ± 13\*
  dBP (mm Hg)               81 ± 10             83 ± 10              85 ± 9\*
  BNP (pg/mL)               19.8 (10.2--37.6)   13.8 (8.0--31.8)\*   14.2 (8.0--28.7)\*
  TC (mg/dL)                189 (170--207)      197 (179--215)\*     196 (173--224)^∗\#^
  TG (mg/dL)                84 (64--111)        104 (79--135)\*      184 (151--256)\*
  HDLc (mg/dL)              59 ± 14             54 ± 12\*            43 ± 12^∗\#^
  LDLc (mg/dL)              117 ± 28            128 ± 27\*           123 ± 29^∗\#^
  eGFR (mL/min/1.73 m^2^)   83 (72--92)         76 (66--86)\*        77 (67--89)\*
  H-FABP (ng/mL)            3.2 (2.4--4.5)      3.6 (2.7--4.8)\*     3.8 (2.8--4.9)\*

BMI: body mass index; BNP: brain natriuretic peptide; TC: total cholesterol; TG: triglyceride; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; H-FABP: heart type fatty acid binding protein; sBP: systolic blood pressure; dBP: diastolic blood pressure; Data are presented as mean ± S.D or median (interquartile range). \**P* \< 0.05 versus IR (−); ^\#^ *P* \< 0.05 versus IR (+).

###### 

Comparisons of clinical characteristics of patients with and without IR and Mets in female.

                            IR (−)              IR (+)                Mets (+)
  ------------------------- ------------------- --------------------- ---------------------
  Age (years)               62 ± 10             62 ± 10               64 ± 8
  BMI (kg/m^2^)             22.0 ± 3.0          24.5 ± 3.4\*          26.4 ± 2.7^∗\#^
  sBP (mm Hg)               130 ± 16            135 ± 15\*            144 ± 12^∗\#^
  dBP (mm Hg)               75 ± 9              78 ± 9\*              83 ± 8^∗\#^
  BNP (pg/mL)               23.3 (14.0--37.0)   18.5 (10.8--30.5)\*   19.8 (10.7--38.0)\*
  TC (mg/dL)                204 (185--223)      209 (190--232)\*      212 (192--237)\*
  TG (mg/dL)                79 (62--102)        100 (76--123)\*       166 (149--186)^∗\#^
  HDLc (mg/dL)              64 ± 14             61 ± 13\*             48 ± 11^∗\#^
  LDLc (mg/dL)              127 ± 28            133 ± 29\*            132 ± 29\*
  eGFR (mL/min/1.73 m^2^)   107 (98--126)       104 (96--123)         101 (86--121)\*
  H-FABP (ng/mL)            3.3 (2.5--4.4)      3.6 (2.6--4.8)\*      3.5 (2.7--5.2)\*

BMI: body mass index; BNP: brain natriuretic peptide; TC: total cholesterol; TG: triglyceride; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; H-FABP: heart type fatty acid binding protein; sBP: systolic blood pressure; dBP: diastolic blood pressure; Data are presented as mean ± S.D or median (interquartile range). \**P* \< 0.05 versus IR (−); ^\#^ *P* \< 0.05 versus IR (+).

###### 

Univariate and multivariate logistic analysis for high serum level of H-FABP.

  Variables                                         OR      95% CI         *P* value
  ------------------------------------------------- ------- -------------- -----------
  Univariable analysis                                                      
   Age (per 5 years increase)                       1.716   1.552--1.908   \<0.0001
   Male                                             1.396   1.022--1.905   0.0357
   BMI                                              1.224   0.881--1.701   0.2288
   BNP                                              1.004   1.002--1.006   0.0008
   sBP                                              1.493   1.076--2.071   0.0164
   dBP                                              1.110   0.784--1.570   0.5565
   LDLc                                             0.682   0.468--0.995   0.0468
   HDL (\<40 mg/dL in male, \<50 mg/dL in female)   1.532   0.774--3.035   0.2209
   TG (above 150 mg/dL)                             0.730   0.377--1.415   0.3514
   TC (above 220 mg/dL)                             0.960   0.670--1.377   0.8265
   IR (presence of IR)                              1.399   1.002--1.953   0.0487
  Multivariable analysis                                                    
   Age (per 5 years increase)                       1.707   1.531--1.908   \<0.0001
   Male                                             1.258   0.904--1.750   0.1726
   BNP                                              1.022   0.719--1.454   0.9023
   sBP                                              1.041   0.736--1.472   0.8219
   IR (presence of IR)                              1.574   1.100--2.251   0.0131

OR: odds ratio; CI: confidence interval; BMI: body mass index; BNP: brain natriuretic peptide; TC: total cholesterol; TG: triglyceride; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; H-FABP: heart type fatty acid binding protein; sBP: systolic blood pressure; dBP: diastolic blood pressure.
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